C
넥스트바이오메디컬
389650KOSDAQ의료용 기기 제조업50.5 / 100
Reference Date: 2026-06-10
Financial Score15.0 / 40
News Sentiment19.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 27.4% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
NextBioMedical is a biopharma company specializing in drug delivery systems, biocompatible medical devices, and oncology treatments. It focuses on developing pharmaceutical-medical device convergence products, particularly drug-eluting beads for liver cancer therapy and interventional radiology technologies.
Number of Employees
81people
Average Salary
45.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 21.514.0Point
PBR
7.05Industry Average 1.380.0Point
5.1x industry avg (risky)
ROE
-0.67Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
6.47Industry Average 11.655.0Point
Lower than industry avg (good)
Trend 2024~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲72.7% (1-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲79.9% (1-year basis)
ROE Trend
0.0 / 4
Detailed News Sentiment
5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 78
- Neutral
- Positive넥스트바이오메디컬, ‘월드 베스트 병원 2026’ 선정 의료기관과 임....
넥스트바이오메디컬의 주요 임상시험이 세계 최고 수준의 병원들에서 진행되어 기업의 기술력과 신뢰성이 인정받았다.
- Positive넥스트바이오메디컬, '넥스피어에프' 관련 기술 미국 특허 등록
넥스트바이오메디컬의 '넥스피어에프' 기술이 미국 특허 등록으로 글로벌 경쟁력 강화에 기여할 것으로 예상됩니다.
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 40,950Won52-week high 98,00052-week low 40,800
1-month return0.0Point
1m -27.39% (strong drop)
Volume trend5.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-26
- Neutral분기보고서 (2026.03)2026-05-15